CTRI/2020/07/026440尚未招募3 期
Efficacy and safety of combination of Silodosin and Tadalafil vs. Silodosin or Tadalafil alone in patients with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH): An open label randomized control trial
I0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •An International Prostatic Symptom Score (IPSS) of more than 7,
- •Maximum Urinary Flow Rate (Qmax) less than 15 ml/second with minimum voided volume of more than 150 ml at screening,
- •Willing and able to give written informed consent and comply with study procedures,
- •Patients agreed not to use BPH medications during the research other than the study medications.
排除标准
- •Known allergy or contraindications to Silodosin and Tadalafil and use of finasteride or dutasteride,
- •History of syncope, and orthostatic hypotension,
- •Bladder outlet obstruction due to cancer, calculi or stricture,
- •Previous Transurethral Resection of the Prostate (TURP),
- •Any neurological disorders affecting storage and voiding functions,
- •Prostatitis,
- •PSA greater than 4 ng/ml,
- •An episode of acute urinary retention within 4 weeks of study initiation,
- •Documented urinary tract infection,
- •Poorly controlled diabetes mellitus,
- •Poorly controlled hypertension.
研究者
相似试验
尚未招募
4 期
A study to compare safety and efficacy of silodosin versus mirabegron in patients with lower uretericstoneCTRI/2023/08/057036Dr Rajendera Prasad Government Medical College, Kangra at Tanda, Himachal Pradesh India
进行中（未招募）
1 期
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseBenign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert pressure on the lumen of the prostatic urethra, resulting in a gradual obstruction to urine flow.MedDRA version: 8.1 Level: LLT Classification code 10004446EUCTR2005-005665-11-GBRecordati S.p.A1,400
进行中（未招募）
不适用
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseEUCTR2005-005665-11-FIRecordati S.p.A1,400
进行中（未招募）
1 期
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseBenign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert pressure on the lumen of the prostatic urethra, resulting in a gradual obstruction to urine flow.MedDRA version: 8.1Level: LLTClassification code 10004446EUCTR2005-005665-11-ESRecordati S.p.A1,400
尚未招募
不适用
The efficacy combined therapy with silodosin and solifenasin in female overactive bladder patients with voiding symptomKCT0003202Korea University Ansan Hospital338